SCHEMBL16631477

SCHEMBL16631477

Cc1nc2cc(C)c(=O)nc-2[nH]c1C(F)(F)F

nearest known ligand 0.33

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 1/20 0.33
PDE3A Q14432 1/20 0.33
AR P10275 1/20 0.31
USP2 O75604 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18081973 0.86 PDE3B (0.32) PDE3BPDE3AARUSP2TSHR
SCHEMBL16631469 0.81 OPRK1 (0.30)
SCHEMBL18081955 0.79 PARP1 (0.30)
SCHEMBL16631934 0.78 SMPD3 (0.36)
SCHEMBL18081755 0.78 HPGD (0.36) PDE3BPDE3AUSP2TSHR
SCHEMBL18081917 0.75 PDE3B (0.35) PDE3BPDE3AUSP2TSHR
SCHEMBL16631454 0.74 TNKS (0.34) PDE3BPDE3AARUSP2TSHR
SCHEMBL16631455 0.74 PDE3B (0.35) PDE3BPDE3AUSP2TSHR
SCHEMBL18081810 0.74 DGAT1 (0.42)
SCHEMBL18080245 0.73 KDM4E (0.38) TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
WO-2015051173-A2 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF POLRMT, POLN, NSUN3 PDE3B 1568/4885PDE3A 1692/4885AR 4464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.